China announced China’s pancreatic cancer treatment drug Yanda (chemical name: Irinotecan liposome injection) in April 12, 2022. It was approved by the China National Drug Administration and was combined with 5- fluorouracil (5-FU) and folic acid (LV) for metastatic pancreatic cancer after gemcitabine treatment.
Pancreatic cancer is known as “the king of cancer” because of its hidden symptoms, high malignancy and high mortality. The latest China data show that pancreatic cancer has a five year survival rate of less than 10%, which is significantly lower than China’s overall cancer survival rate of 40.5%, and is one of the lowest survival rates. According to the latest global cancer burden data in 2020, 124994 new pancreatic cancer cases occurred in 2020, and 121853 deaths occurred in China. Meanwhile, the incidence rate of pancreatic cancer is increasing year by year. The early diagnosis rate is less than 5%. About 60% of patients have been transferred at the first time, and 30% of them have been in the local progress at the first diagnosis, and there are still many non satisfied needs.
China’s pancreatic cancer treatment plan was approved by Yi anda’s breakthrough in the past 23 years after the approval of pancreatic cancer in 1999. Pancreatic cancer has brought innovative solutions to pancreatic cancer patients.
China’s China pancreatic cancer clinic guidelines (2018 Edition), the Chinese society of Clinical Oncology (CSCO), guideline for diagnosis and treatment of pancreatic cancer, has been recommended by China National Institute of Clinical Oncology (CSCO), China’s Clinical Oncology Society (2020). And China pancreatic cancer China Specialized Committee Association for pancreatic cancer, China’s comprehensive guideline for pancreatic cancer (2020 Edition), and the Chinese pancreatic cancer treatment guideline (2021), the Chinese pancreatic surgery division of the Chinese Medical Association, all of which are recommended as second-line treatment for pancreatic cancer.
It is worth mentioning that in August 2021, yianda, as a clinically urgently needed imported drug, was approved by Hainan Provincial Food and drug administration. It can prescribe overseas special drugs in medical institutions in Hainan to provide valuable treatment schemes for patients with metastatic pancreatic ductal adenocarcinoma. At the same time, yianda, as a clinically urgently needed imported drug, has also been included in Lecheng special drug insurance and Beijing Pratt & Whitney health insurance. During the insurance period, patients who meet the conditions can settle a certain amount of claims for yianda.
Mr. Stefan, general manager of Servier China, China’s Chinese mainland approved the breakthrough of the treatment of metastatic pancreatic cancer after gemcitabine treatment. It also marks the emergence of scherya as one of the important participants in the field of cancer. Meeting the needs of patients is the core consideration of all the business of Schwei group. Schw group has already made the fight against cancer as one of the core development strategies of the group and has invested 50% of the group’s R & D expenses. Enter the field of oncology. In the future, we look forward to bringing more exciting and innovative treatments to cancer patients. “
\u3000\u30001. Healthy China action (20192030) formulated by the healthy China action Promotion Committee in 2019
\u3000\u30002. Chinese Medical Association Oncology Association expert consensus on early diagnosis and treatment of pancreatic cancer (2020)
